|Bid||49.18 x 3100|
|Ask||50.00 x 1000|
|Day's range||48.80 - 49.21|
|52-week range||44.76 - 54.26|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||18.39|
|Forward dividend & yield||1.93 (3.93%)|
|Ex-dividend date||03 May 2021|
|1y target est||64.63|
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent asthmaData reinforce well-established safety profile of Dupixent PARIS and TARRYTOWN, N.Y. – October 20, 2021 - The U.S. Food and D
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
Dr. Stella Safo, NYC-based HIV Primary Care Physician, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.